Organigram Global Inc. (OGI) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Organigram Global Inc. (NASDAQ: OGI) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $0.93 (-2.85% 1D, market cap $135.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OGI ranks #165 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KZIA (Kazia Therapeutics Limited) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $135.6M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).
For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #165 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 49.6 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±7.9% realized swing band)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 62/100 (C) score, OGI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.04) or 200D SMA ($1.20) invalidates the momentum regime and cuts Target Base ($0.95) toward Bear Floor ($0.74).
Organigram Global Inc. (OGI) dropped -2.85% to $0.93, trading at 6% of its 52-week range ($0.85 – $2.24). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
SNDL Inc. posted record free cash flow but faces near-term earnings pressure from restructuring and product cuts. Click for this earnings update of SNDL stock.
Key Takeaways; Cannabis Sector Aurora Cannabis Rejected Curaleaf’s $5-a-Share Takeover Bid, Despite Exploring Alternatives Cronos Group Completed €57.5 Million Acquisition of Dutch Cannabis Producer CanAdelaar Tilray Med
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OGI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OGI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Organigram Global Inc. (OGI) ranks #165 by composite RQD confidence (62/100, grade C) and #623 by equity capitalization ($135.4M). Within this direct 5-issuer industry benchmark cohort, OGI leads on earnings valuation at N/A trailing P/E, while SPRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OGI
ACTIVE
Organigram Global Inc. | C | 62/100 | — | — | — | -2.85% | $135.4M | Benchmark Subject |
| KZIA Kazia Therapeutics Limited | C- | 61/100 | — | — | — | -2.52% | $135.6M | /kzia-vs-ogi → |
| SPRB Spruce Biosciences Inc. | D- | 42/100 | — | — | -35.0% | -0.92% | $134.6M | /sprb-vs-ogi → |
| CATX Perspective Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -1.71% | $133.6M | /catx-vs-ogi → |
| NBP NovaBridge Biosciences | D- | 38/100 | — | — | -35.0% | -1.24% | $139.6M | /nbp-vs-ogi → |
Organigram Global Inc. (OGI) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $135.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Organigram Global Inc. (NASDAQ: OGI) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $0.93 (-2.85% 1D, market cap $135.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OGI ranks #165 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KZIA (Kazia Therapeutics Limited) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $135.6M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).
For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #165 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
OGI last traded at $0.93 (-2.85% on volume of 205,068 shares), positioning the stock -10.58% below its 50-day simple moving average ($1.04) and -22.50% below its 200-day simple moving average ($1.20). Across its 52-week range of $0.85 to $2.24, OGI sits at the 5.8% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($1.00 to $1.00).
Why OGI Stock dropped -2.85% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Per the Roarable RQD rating, OGI scores 62 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 12 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 13 of 20 (institutional accumulation and options positioning); Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 15 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillar is the cash engine, where the source data reports zero ROIC and zero FCF yield, meaning the rating does not credit the company with current cash generation. The forensic balance sheet and macro fit pillars are the strongest relative to their weight, with a Beta of 1.0 indicating market-level sensitivity and a Piotroski F-Score of 6 of 9 suggesting moderate financial-quality signals. The insider conviction pillar, at 9 of 20, is the lowest score and reflects weaker insider signal flow in the rating's inputs. The overall verdict is a balanced one: upside depends on whether institutional accumulation and cash-generation improvements materialize, while valuation and profitability tradeoffs remain unresolved in the source data.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector reference available is Health Care / Biotechnology: Pharmaceutical Preparations. An investor should note that the cannabis-brand discontinuation items suggest product-line exposure, but the source provides no supply-chain nodes to trace its ripple effects.
Real-time company headlines, analyst actions, and sector developments for Organigram Global Inc. (OGI) • Click "Debate This Headline" to argue it in the Roar Pit below
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Welcome to the OGI (Organigram Global Inc.) Roar Pit. Current RQD Composite is 62/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on OGI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Organigram Global Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on OGI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.96 (52-wk range $0.80 - $1.02), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).